6 min. Read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases

Help me get ahead. $200/year

Newsletters

Spring Health’s new biz. Coca-Cola’s benefits.

2.02.24

8 min. Read

Facebook’s RCT for AI bot Zenny. More trials

1.26.24

7 min. Read

Which virtual clinics got FTC-OCR letters?

1.19.24

6 min. Read

Digging into the Omada-Amazon marketing deal.

1.12.24

9 min. Read

FDA de novo for Google smartphone thermometer.

1.05.24

6 min. Read

New state launches for Midi Health, HeyJane, Swing Care and more

12.21.23

6 min. Read

PDT-to-virtual-clinic trend continues. HCPCS tweaks.

12.15.23

8 min. Read

Teladoc customer wins. Pricing database updates

12.08.23

5 min. Read

Mahana Tinnitus. New CPT hopefuls. Better cuts salaries

12.01.23

6 min. Read

UnitedHealth’s employee benefits. Omada signals IPO. Detailed Spring Health pricing.

11.21.23

9 min. Read

Scoop: Amwell in talks to buy Omada

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.